NOVOLIN R (human insulin) by Novo Nordisk. Approved for insulin [epc]. First approved in 1991.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
NOVOLIN R is a rapid-acting human insulin formulation indicated for the treatment of diabetes mellitus. It works by replacing deficient endogenous insulin, facilitating glucose uptake and metabolism in target tissues. This is a foundational insulin product approved in 1991 that remains widely used despite newer analog insulins.
Product is in late-stage lifecycle with declining market share; commercial team size likely contracted or consolidating focus to adjacent products.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Defining the Human Insulin Resistance Molecular Network; SIGNATURE
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
Worked on NOVOLIN R at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moNOVOLIN R career opportunities are concentrated in commercial execution and market defense as the product approaches loss of exclusivity. Roles focus on maximizing remaining market share, managing payor relationships, and orchestrating the transition to a generic-competitive environment. This is a defensive, cost-management portfolio assignment rather than a growth opportunity.